Ally Financial enters September with a tailwind from the Street but a headwind from price — and the gap between analyst conviction and recent stock performance is the week's defining tension.
Raymond James moved decisively on Wednesday, reinstating coverage with a Strong Buy rating and a $55 target. That's a 31% premium to Tuesday's close of $41.85. The reinstatement adds weight to an already bullish consensus: 11 buy-side ratings, a mean target near $53.77, and a string of target hikes from RBC, BofA, and Wells Fargo over the summer. The lone dissent in recent activity came from Truist, which trimmed its target to $51 from $54 in early August while holding its Buy rating — a mild acknowledge of near-term pressure rather than a structural concern. Overall, the Street is not walking away from Ally; it's paying a higher price for patience.
The short side tells a quieter story. Short interest has drifted lower through August, easing from around 13.6 million shares in late July to roughly 12.8 million now — about 4.2% of the free float. That's a meaningful decline of nearly 3% across the month. Borrowing costs are low at 0.32%, down sharply from a brief spike above 0.65% in mid-August, and the lending pool is extraordinarily loose: availability is running at more than 7,700% of short interest, meaning there are roughly 297 million shares available to borrow against fewer than 13 million currently shorted. This is not a market where short sellers are pressed, squeezed, or crowding in — they've been trimming, not building. The ORTEX short score of 39.3 corroborates that picture, sitting in the bottom two-fifths of the universe and barely moving over the past two weeks.
Options are tilting modestly in the bulls' favour. The put/call ratio of 0.63 is slightly below its 20-day average of 0.65 — a reading that's near the middle of its historical range and well away from the 52-week high of 1.41 that marked last year's defensive peak. There's no sign of hedging pressure or outsized downside demand. Positioning, taken together, looks relaxed rather than cautious.
The valuation case is similarly understated. Ally trades at roughly 7x earnings and 0.84x book — multiples that have drifted marginally lower over the past 30 days even as the Raymond James reinstatement lands. The dividend score ranks in the 93rd percentile of the universe, though the dividend history in the data is stale and shouldn't be treated as a current yield indication. The bull case rests on consumer auto loan resilience — the portfolio edged up to $83.9 billion last quarter — and margin improvement from here. Bears point to the 2.1% sequential decline in net financing revenues and the shrinkage in the commercial auto book. On factor scores, earnings momentum is middling (61 on the 30-day reading, 46 on 90-day), and the 12-month forward EPS growth rank is weak at 20 — the Street sees improvement, but slowly.
Institutional holders reinforce the stability read. BlackRock lifted its position to 28.6 million shares as of late July. Berkshire Hathaway trimmed slightly to 27 million but remains a near-9% owner. Harris Associates holds another 8.7% and added modestly in Q2. These are patient, value-oriented holders who collectively own more than a quarter of the company. No 13D activist is on the register. The ownership picture is orderly.
The next catalyst is Q3 earnings, pencilled in for October 16. The last two prints both resulted in small negative day-one moves — down 1.9% in July and 2.7% in April — with the weakness extending into the following week. With the stock already down 3.4% over the past month and sitting roughly 22% below the consensus price target, the question heading into that date is whether credit quality data can close the gap between Street optimism and market scepticism.
See the live data behind this article on ORTEX.
Open ALLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
